HT and SERMs in the long-term management of osteoporosis

Minerva Ginecologica

Volumn 64, Issue 3, 2012, Pages 195-205

  Tuppurainen, M ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Bone, density; Fractures, bone; Osteoporosis, postmenopausal; Raloxifene; Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

ALENDRONIC ACID; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; LASOFOXIFENE; NORETHISTERONE ACETATE; OSPEMIFENE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGING; AMENORRHEA; BONE DENSITY; BREAST CANCER; COUGHING; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM POLYP; FRACTURE; FRACTURE REDUCTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LEG CRAMP; LONG TERM CARE; LOW DRUG DOSE; MASTALGIA; MENOPAUSAL SYNDROME; MUSCLE CRAMP; OSTEOLYSIS; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VULVOVAGINITIS;

BONE DENSITY CONSERVATION AGENTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INDOLES; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84864386187     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Harvey N, Dennison E, Cooper C. Osteoporosis: Impact on health and economics. Nat Rev Rheumatol 2010;6:99-105.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33.
3. Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD. Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int 2011;22:2439-48.
4. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-94.
5. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-12.
6. Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F. Development and use of FRAX in osteoporosis. Osteoporos Int 2010;21(Suppl 2):S407-13.
7. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX((R)) with and without bone mineral density. Calcif Tissue Int 2012;90:1-13.
8. Tuppurainen M, Honkanen R, Kroger H, Saarikoski S, Alhava E. Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women - the results of the baseline postal enquiry of the Kuopio osteoporosis risk factor and prevention study. Maturitas 1993;17:89-100.
9. Honkanen RJ, Honkanen K, Kroger H, Alhava E, Tuppurainen M, Saarikoski S. Risk factors for peri-menopausal distal forearm fracture. Osteoporos Int 2000;11:265-70.
10. Mosekilde L, Beck-Nielsen H, Sorensen OH, Nielsen SP, Charles P, Vestergaard P et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish osteoporosis prevention study. Maturitas 2000;36:181-93.
11. Sirola J, Salovaara K, Tuppurainen M, Jurvelin JS, Alhava E, Kroger H. Sister's fracture history may be associated with perimenopausal bone fragility and modifies the predictability of fracture risk. Osteoporos Int 2009;20:557-65.
12. Huopio J, Kroger H, Honkanen R, Saarikoski S, Alhava E. Risk factors for perimenopausal fractures: A prospective study. Osteoporos Int 2000;11:219-27.
13. Leboime A, Confavreux CB, Mehsen N, Paccou J, David C, Roux C. Osteoporosis and mortality. Joint Bone Spine 2010;77(Suppl 2):S107-12.
14. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in post-menopausal women. the framingham study. N Engl J Med 1987;317:1169-74.
15. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. study of osteoporotic fractures research group. Ann Intern Med 1995;122:9-16.
16. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The women's health initiative randomized trial. JAMA 2003;290:1729-38.
17. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The women's health initiative randomized controlled trial. JAMA 2004;291:1701-12.
18. Komulainen MH, Kroger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R et al. HRT and vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 2008;61:85-94.
19. Heikkinen J, Vaheri R, Haapalahti J, Timonen U. A 10-year follow-up of the effect of continuous-combined hormone replacement therapy and its discontinuation on bone in postmenopausal women. Menopause Int 2008;14:70-7.
20. Meyer HE, Lofthus CM, Sogaard AJ, Falch JA. Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Osteoporos Int 2009;20:827-30.
21. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
22. Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S et al. Hormone therapy prescribing patterns in the united states. Obstet Gynecol 2004;104(5 Pt 1):1042-50.
23. Parente L, Uyehara C, Larsen W, Whitcomb B, Farley J. Long-term impact of the women's health initiative on HRT. Arch Gynecol Obstet 2008;277:219-24.
24. Barbaglia G, Macia F, Comas M, Sala M, del Mar Vernet M et al. Trends in hormone therapy use before and after publication of the women's health initiative trial: 10 years of follow-up. Menopause 2009;16:1061-4.
25. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010;17:242-55.
26. Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A, Felsenberg D et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011;89:91-104.
27. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of osteoporotic fractures research group. N Engl J Med 1998;339:733-8.
28. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The study of osteoporotic fractures. J Clin Endocrinol Metab 1998;83:2239-43.
29. Bagur A, Oliveri B, Mautalen C, Belotti M, Mastaglia S, Yankelevich D et al. Low levels of endogenous estradiol protect bone mineral density in young post-menopausal women. Climacteric 2004;7:181-8.
30. Mellstrom D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, Oden A et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008;23:1552-60.
31. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010;95:3-10.
32. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 2001;285:2891-7.
33. Cauley JA, LaCroix AZ, Robbins JA, Larson J, Wallace R, Wactawski-Wende J et al. Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The women's health initiative randomized trial. Osteoporos Int 2010;21:167-77.
34. Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2-6.
35. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: A randomized controlled trial. JAMA 2003;290:1042-8.
36. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstet Gynecol 2004;104:443-51.
37. Fadanelli ME, Bone HG. Combining bisphosphonates with hormone therapy for postmenopausal osteoporosis. Treat Endocrinol 2004;3:361-9.
38. Tuppurainen M, Harma K, Komulainen M, Kiviniemi V, Kroger H, Honkanen R et al. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic post-menopausal women: A 5-year follow-up. Maturitas 2010;66:423-30.
39. Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf 2007;16:17-27.
40. Cumming GP, Currie HD, Panay N, Moncur R, Lee AJ. Stopping hormone replacement therapy: Were women ill advised? Menopause Int 2011;17:82-7.
41. Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: Results from a prospective study in a large health management organization. Menopause 2011;18:1172-7.
42. Sornay-Rendu E, Garnero P, Munoz F, Duboeuf F, Delmas PD. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: The OFELY study. Bone 2003;33:159-66.
43. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study. Bone 2004;34:728-35.
44. Middleton ET, Steel SA. The effects of short-term hormone replacement therapy on long-term bone mineral density. Climacteric 2007;10:257-63.
45. Simon JA, Wehren LE, Ascott-Evans BH, Omizo MK, Silfen SL, Lombardi A. Skeletal consequences of hormone therapy discontinuance: A systematic review. Obstet Gynecol Surv 2006;61:115-24.
46. Bolognese MA. SERMs and SERMs with estrogen for postmenopausal osteoporosis. Rev Endocr Metab Disord 2010;11:253-9.
47. Komm BS, Chines AA. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas 2012;71:221-6.
48. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
49. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
50. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
51. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-8.
52. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 1999;282:637-45.
53. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Anti-vertebral fracture efficacy of raloxifene: A meta-analysis. Osteoporos Int 2006;17(2):313-6.
54. Jolly EE, Bjarnason NH, Neven P, Plouffe L,Jr, Johnston CC,Jr, Watts SD et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-44.
55. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
56. Mosca L, Grady D, Barrett-Connor E, Collins P, Wenger N, Abramson BL et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009;40:147-55.
57. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A et al. Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to evista (CORE) study. J Bone Miner Res 2005;20:1514-24.
58. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17.
59. Duggan ST, McKeage K. Bazedoxifene: A review of its use in the treatment of postmenopausal osteoporosis. Drugs 2011;71:2193-212.
60. Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-35.
61. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34.
62. Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D et al. for the Bazedoxifene Study Group. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351-63.
63. de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011;22:567-76.
64. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52.
65. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24.
66. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in post-menopausal women. Menopause 2010;17:281-9.
67. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM et al. Lasofoxifene in post-menopausal women with osteoporosis. N Engl J Med 2010;362:686-96.
68. Ensrud K, LaCroix A, Thompson JR, Thompson DD, Eastell R, Reid DM et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial. Circulation 2010;122:1716-24.
69. LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in post-menopausal osteoporotic women. J Natl Cancer Inst 2010;102:1706-15.
70. Goldstein SR, Neven P, Cummings S, Colgan T, Runowicz CD, Krpan D et al. Postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 2011;18:17-22.
71. Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 2011;26:397-404.
72. Komi J, Lankinen KS, DeGregorio M, Heikkinen J, Saarikoski S, Tuppurainen M et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006;24:314-8.
73. Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal phase 3 study. Menopause 2010;17:480-6.
74. Ji J, Sundquist K, Sundquist J. Cancer risk after hospitalization for osteoporosis in Sweden. Eur J Cancer Prev 2011 [Epub ahead of print].
75. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: A systematic epidemiological review. Osteoporos Int 2009;20:1633-50.